Spevigo

Spesolimab is a humanised antagonistic monoclonal immunoglobulin G1 (IgG1) antibody blocking human interleukin-36 receptor (IL36R) signalling. Binding of spesolimab to IL36R prevents the subsequent activation of IL36R by cognate ligands (IL36 α, β and γ) and downstream activation of pro inflammatory and pro-fibrotic pathways. IL36R signalling is differentiated from tumour necrosis factor alpha (TNF-α), integrin and interleukin-23 (IL-23) inhibitory pathways by directly and simultaneously blocking both inflammatory and pro-fibrotic pathways. Genetic human studies have established a strong link between IL36R signalling and skin inflammation.

Following treatment with Spevigo in patients with generalised pustular psoriasis (GPP), reduced levels of C-reactive protein (CRP), interleukin (IL)-6, T-helper cell (Th1/Th17) mediated cytokines, keratinocyte-mediated inflammation, neutrophilic mediators, and proinflammatory cytokines were observed in serum and skin at Week 1 compared to Baseline and was associated with a decrease in clinical severity. These reductions in biomarkers became more pronounced at the last measurement at Week 8 in Effisayil-1.